% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • dinepat203 dinepat203 Oct 25, 2012 1:48 PM Flag

    Remember ISIS has GENZYME- SANOFI Mkt Muscle.

    Kynamro, co-developed by Isis and Sanofi unit Genzyme, is intended to reduce bad cholesterol in patients with a lipid disorder, who are already on a stable regimen of lipid-lowering therapies but require additional treatment.

    The disorder, called familial hypercholesterolemia, is a genetic disease that results in elevated bad cholesterol levels and increased risk of premature heart disease.

    The FDA reviewers said Kynamro was highly effective in reducing bad cholesterol over 26 weeks according to both their analyses and data submitted by the companies.

2.03-0.04(-1.93%)1:34 PMEDT